Post subtotal thyroidectomy calciphylaxis with normal calcium phosphorus product following kidney transplantation: a case report

Abstract

Cutaneous calciphylaxis can occur early or late after kidney transplantation. We report a 43-year-old female with end stage renal failure (ESRD) secondary to unknown cause, who was on dialysis for 15 years and received deceased kidney transplant 3 years ago. She had cutaneous calciphylaxis lesions confirmed by biopsy, involving the medial aspect of the thighs bilaterally and a large necrotic ulcer on the posterior aspect of the left thigh. The patient had no classic risk factors. She had subtotal parathyroidectomies but had normal serum calcium, phosphate and parathyroid hormone level. The clinical outcome of this case was favorable and highlights some fundamental issues relating to management.

Keywords: post transplantation, calciphylaxis, hyperparathyroidism, calcium-phosphate product, necrotizing livedo reticularis

Abbreviations: ESRD, end stage renal failure; PTH, parathyroid hormone

Introduction

Calciphylaxis represent a disease in which abnormally the calcium deposit in the walls of small- and medium-sized arteries causing ischaemic necrosis of the tissues supplied by those arteries that is called necrotizing livedo reticularis. First cases reported having calciphylaxis were among dialysis patients. Therefore, it was first named as calcific uraemic arteriolopathy however it was found that it is not exclusive to uraemic patients but observed as well in non-uraemic conditions including: primary hyperparathyroidism, malignancy, autoimmune diseases and even after kidney transplantation. Calciphylaxis is a serious disease that can be fatal characterized by painful skin lesions localized on the peripheral extremities. Patient survival is less than 40%.

Calciphylaxis is a progressive disease that usually affects the distal parts of lower limbs. In addition, it may affect any part of the body, including visceral tissue. Pathogenesis of calciphylaxis is not well known but may be due to abnormal calcium phosphate homeostasis. There are many risk factors associated with the incidence of calciphylaxis; the most common is hyperparathyroidism and the dysregulation of calcium-phosphate metabolism leading to abnormal calcium phosphate product. Diseases associated with attherosclerosis like diabetes mellitus, obesity, coagulopathies, and warfarin or iron dextran treatment may contribute as well in calciphylaxis. A few reported patients suffering calciphylaxis been reported after kidney transplantation. In here, we describe an unusual presentation of a case of calciphylaxis one-year post subtotal parathyroidectomy in a kidney transplanted patient with normal serum calcium & phosphate product levels with superimposed infection.

Case presentation

A 43-year-old female with ESRD, on dialysis for 15 years was received a kidney graft from deceased donor on 24th Feb 2009 with smooth post operative course and good initial graft function with no rejection episodes. She was admitted in July 2009 with corrected calcium 3.27mmol/L, phosphate 0.62mmol/L, PTH 19.8pmol/l (n. 0.7-5.6pmol/l). Subsequent to that she had subtotal-parathyroidectomy with normalization of corrected calcium and phosphate level and calcium-phosphate product of less than four. She was not on warfarin, calcium supplements nor alfacalcidol. She had good graft function with creatinine ranging between 79-106µmol/L. Her treatment was prednisolone 5mg OD, Tacrolimus 1.0mg BID, Mycophenolat Mofetil 1.0gm BID and Amlodipine 5mg OD. She was re-admitted on 29th July 2012 with a complaint of sudden onset of painful lesions bilaterally on the medial aspect of her thighs. They appeared within 48 hours prior to admission and were not associated with a history of trauma. Serum levels of calcium, phosphate and calcium-phosphate product were found to be normal. Clinically, both lesions were well demarcated, gangrenous in appearance and foul smelling (Figure 1). Painful nodules were palpable on the medial side of the right thigh. Peripheral pulses were intact.

Her BMI was 22.3kg/m² and results of a laboratory work-up for vasculitides were negative. Protein electrophoresis showed low serum albumin and hypo-gammaglobulinemia. The patient’s hemoglobin level was 12.1g/dL, hematocrit 36.6%; normal; corrected serum calcium 2.58mmol/L; phosphate 1.09mmol/L; Mg++ 0.66mmol/L; alkaline phosphatase 152 IU/L; urea 7.5mmol/L; serum creatinine 98µmol/L; albumin 26gm/L.

Swabs taken from this lesion grew mix growth of gram positive cocci. A wedge biopsy of the lesion confirmed the diagnosis of calciphylaxis (Figure 2). A second biopsy shows cocci and hyphae
confirming bacterial and fungal infection. Intravenous antibiotic was immediately introduced. Based on biopsy and culture results voriconazole was added for two weeks as it is the treatment of choice in seriously invasive candidiasis and aspergillosis. Modification of tacrolimus level was needed as therapeutic level reached 20ng/ml with rise of serum creatinine from 98 to 154µmol/L. Withdrawal of half dose of tacrolimus the level returned back to 8.9 ng/ml and creatinine level normalized. Our patient had aggressive treatment with antibiotics including Piperacillin/tazobactam, Meropenem and voriconazole this treatment resulted in compacting infection and survival of the patient. Over a period of one month, new lesions had fully resolved while old lesion ulcerate forming 20 x 15cm ulcer on the posterior aspect of left thigh with undermined edges and necrotic base that was corrected surgically.

and another case report of late calciphylaxis occurring post kidney transplantation both cases suffered unfavorable outcome. Interestingly, our patient did not have any of the recognizable risk factors associated with the development of calciphylaxis. The clinical outcome in our case has been favorable and emphasizes the importance of early diagnosis, aggressive antimicrobial therapy, wound management and minimization of maintenance immunosuppression. Calciphylaxis may present in the form of mild erythematous patches, painful nodules, livido reticularis or necrotic ulcerating lesions, giving various possible differential diagnoses.

Histopathology is the gold standard diagnosis for calciphylaxis through a diagnostic biopsy to exclude other causes of cutaneous lesions. The standard management includes treatment of hyperparathyroidism; reduction of calcium-phosphate product, culture based anti-microbial therapy if there was infection and meticulous care of the wound. Several therapeutic approaches for the treatment of calciphylaxis have been reported starting with parathyroidectomy then less commonly hyperbaric oxygen therapy, sodium thiosulfate infusion, tissue plasminogen activator and recently bisphosphonates but none have shown any consistent benefit. Cinacalcet has been prescribed as a treatment of calciphylaxis in patients medically unfit for parathyroidectomy. It suppresses PTH release and has been shown to be effective in cases with high PTH levels as in secondary hyperparathyroidism. Cinacalcet was not introduced in our patient as calcium-phosphate product was normal and PTH level could not be done at the time. In general, calciphylaxis is associated with a poor prognosis if not aggressively managed. Monitoring of the immunosuppressive medications especially calcineurin trough level is mandatory. In conclusion cutaneous calciphylaxis lesions should be promptly managed with meticulous wound care, antimicrobial therapy and the correction of calcium-phosphate product where indicated.

Acknowledgements
None.

Conflict of interest
Author declares that there is no conflict of interest.

References

Post subtotal thyroidectomy calciphylaxis with normal calcium phosphorus product following kidney transplantation: a case report


